Every material Form 8-K Bone Biologics Corp has filed with the SEC since July 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bone Biologics said on September 10, 2026 that it received a Nasdaq letter because its stock closed below $1 per share for 30 consecutive business days. The company has 180 days, until March 9, 2027, to regain compliance, and it plans to seek stockholder approval for a reverse stock split at its upcoming annual meeting. The notice has no immediate effect on the stock's listing, but a failure to regain compliance could lead to delisting proceedings.
Nasdaq letter dated September 10, 2026 cites closing bid price below $1 per share for the last 30 consecutive business days
Compliance period runs 180 calendar days, until March 9, 2027
Regaining compliance requires a closing bid price of at least $1 for 10 consecutive business days
Company intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting
Bone Biologics said it completed a July 2026 private placement with one healthcare-focused institutional investor, with gross proceeds of about $3.0 million before fees and expenses. The company says the financing extends its operating runway through Q2 2027, and the filing contains no revenue or earnings figures.
July 2026 private placement with a single healthcare-focused institutional investor, priced at-the-market under Nasdaq rules, for gross proceeds of about $3.0 million before fees and expenses
Series F and G warrants could add up to about $6.0 million if fully exercised for cash, but the company gives no assurance that any will be exercised
Company expects to complete patient enrollment in its first-in-human NB1 pilot study by year-end
Validated shelf life of rhNELL-1 extended to 29 months in May 2026, up from 24 months in December 2025
Bone Biologics' board voted on July 15, 2026 to postpone the annual stockholder meeting from August 11 to September 28, 2026, so an additional proposal can be included in the proxy statement and stockholders have more time to review it. The company also moved the record date to August 6, 2026 and the deadline for director nominations and other proposals to July 26, 2026. The change is administrative and does not state any financial results.
Annual meeting moved from August 11, 2026 to September 28, 2026, at 11:30 a.m. Eastern Time in Burlington, Massachusetts
New record date set for August 6, 2026
Stockholder deadline for director nominees or proposals is now July 26, 2026
Company plans to file a Definitive Proxy Statement on Schedule 14A with an additional stockholder proposal
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bone Biologics Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →